|
News Briefs Bristol-Myers Squibb Applies to Sell New AIDS Drug in EuropeMay 30, 2002 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Bristol-Myers Squibb said Wednesday it has applied to the European equivalent of the US Food and Drug Administration for clearance to market and sell Atazanavir, a drug currently in development for the treatment of HIV/AIDS. The drug is a viral protease inhibitor that has shown potential for once-daily use, Bristol scientists said. Trials have included more than 1,500 patients whose conditions run the spectrum of HIV infection. Associated Press 05.29.02 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
|